Fraction of gemistocytic astrocytes and immunoexpression of p53 protein in astrocytomas grade II and III (WHO);Índice de astrócitos gemistocíticos e imuno-expressão da proteína p53 em astrocitomas, grau II e III OMS

Arquivos de Neuro-Psiquiatria

Volumn 59, Issue 4, 2001, Pages 926-931

  Martins, Dely Cristina ^a   Stávale, João Norberto ^a,b   Malheiros, Suzana Maria Fleury ^a   Santiago, Lucila Heloisa Simardi ^a   Roman, Leonor Cristina Manoja ^a   Aguiar, Kátia Cilene Carozzi ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Rua Botucatu 740 ^*  (Brazil)

Author keywords

Astrocytoma; Gemistocytes; Glioma; p53

Indexed keywords

PROTEIN P53;

ADOLESCENT; ADULT; ARTICLE; ASTROCYTOMA; BIOSYNTHESIS; BRAIN TUMOR; CHILD; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; PATHOLOGY; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; ENGLISH ABSTRACT; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGE; PROTEIN P53; RETROSPECTIVE STUDIES;

EID: 17144466458     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-282x2001000600016     Document Type: Article

References (30)

1. Hoshino T, Wilson CB, Ellis WG. Gemistocytic astrocytes in gliomas: an autoradiographic study. J Neuropathol Exp Neurol 1975; 34: 263-281.
2. Kros JM, Stefanko SZ, De Jong AA, Van Vroonhoven CC, Van der Heul RO, Van der Kwast TH. Ultrastructural and immunohistochemical segregation of gemistocytic subsets. Hum Pathol 1991; 22: 33-40.
3. Kros JM, Waarsenburg N, Hayes DP, Hop WCJ, Van Dekken H. Cytogenetic analysis of gemistocytic cells in gliomas. J Neuropathol Exp Neurol 2000;59:679-686.
4. Kleihues P, Davis RL, Ohgaki H, Burger PC, Westphal MM, Cavenee WK. Diffuse astrocytomas. In Kleihues P, Cavenee WK (eds.). Pathology and genetics of tumours of the nervous system. Lyon: IARC, 2000: 22-26.
5. Lang FF, Miller DC, Koslow M, Newcomb EW. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumours. J Neurosurg 1994; 81: 427-436.
6. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6:217-224.
7. Kleihues P, Ohgaki H. Genetics of glioma progression and the definition of primary and secondary glioblastoma. Brain Pathol 1997;7:1131-1136.
8. Ohgaki H, Schaüble B, Zur Hansen A, Von Ammon K, Kleihues P. Genetic alterations associated with the evolution and progression of astrocytic brain tuours. Virchows Arch 1995;427:113-118.
9. Watanabe K, Sato K, Biernat W, et al. Incidence and timing of the p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 1997; 3:523-530.
10. Kleihues P, Cavenee WK. Who classification of tumours of the nervous system. In: Kleihues P, Cavanee WK (eds). Pathology and genetics of tumours of the nervous system. Lyon: IARC, 2000: 6-7.
11. Watanabe K, Peraud A, Gratas C, Wakai S, Kleihues P, Ohgaki H. p53 and PTEN gene mutations in gemistocytic astrocytomas. Acta Neuropathol 1998;95:559-564.
12. Ohgaki H, Watanabe K, Peraud A, et al. A case history of glioma progression. Acta Neuropathol 1999;97:525-532.
13. Burger PC, Scheithauer BW. Tumours of neuroglia and choroid plexus epithelium. In Rosai J (ed). Tumors of the central nervous system. Washington: Armed Forces Institute of Pathology, 1994: 25-106.
14. Ellison D, Love S, Chimelli L, et al. Astrocytic neoplasmas. In Ellison D, Love S (eds). Neuropathology. London: Mosby, 1998: 35.1-35.15.
15. McLendon RE, Enterline DS, Tien RD, Thorstad WL, Bruner JM. Tumors of central neuroepithelial origin. In Bigner DD, McLendon RE, Bruner JM (eds.). Russell and Rubinstein's pathology of tumors of the nervous system. 6 Ed. London: Arnold Press, 1998: 307-571.
16. Krouwer HGJ, Davis RL, Silver P, Prados M. Gemistocytic astrocytomas: a reappraisal. J Neurosurg 1991, 74: 399-406.
17. Kösel S, Scheithauer BW, Graeber MB. Genotype-phenotype correlation in gemistocytic astrocytomas. Neurosurgery 2001;48:187-194.
18. Nissl, F. Zur histopathologie der paralytischen rindenerkrankung. Histol Histopathol Arb Grosshirn 1904;1:316-494.
19. Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki, H. Role of gemistocytes in astrocytoma progression. Lab Invest 1997;76:277-284.
20. Mahler-Araújo MB. Análise da participação de gemistocitos na recorrência e progressão das neoplasias astrocíticas difusas. Tese, Faculdade de Medicina de Ribeirão Preto. Ribeirão Preto, 2000.
21. Yaziji H, Massarani-Wajai R, Gujrati M, Kuhns JG, Martin AW, Parker JC. Role of p53 immunohistochemistry in differentiating reactive gliosis from malignant astrocytic lesions. Am J Surg Pathol 1996; 20: 1086-1090.
22. Cunningham JM, Kimmel DW, Scheithauer RB, O'Fallon JR, Novotny PJ, Jenkins RB. Analysis of proliferation makers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg 1997;86:121-130.
23. Vital A, Loiseau H, Kantor G, et al. p53 protein expression in grade II astrocytomas: immunohistochemical study of 100 cases with long-term follow-up. Pathol Res Pract 1998;194:831-836.
24. Rathore A, Kamarajan P, Mathur M, Sinha S, Sarkar C. Simultaneous alterations of retinoblastoma and p53 protein expression in astrocytic tumors. Pathol Oncol 1999;5:21-27.
25. Battifora H. p53 immunohistochemistry: a word of caution. Hum Pathol 1994; 25: 435-436.
26. Bosari S, Viale G. The clinical significance of p53 aberrations in human tumours. Virchows Arch 1995; 427: 229-241.
27. Steilen-Gimbel H, Steudel W.I, Feiden W, Moringlane JR, Henn W, Zang KD. Genetic heterogeneity in human astrocytomas: spatial distribution of P16 and TP53 deletion in biopsies. Cancer Genet Cytogenet 1999; 113:115-119.
28. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC. Somatic point mutations in the p53 gene of human tumours and cell lines: updated compilation. Nucl Acids Res 1996;24:141-146.
29. Furuwatari C, Yagi A, Yamagami O, et al. A comprehensive system to explore p53 mutations. Am J Clin Pathol 1998;110:368-373.
30. Harris CC, Hollstein M. Clinical implications of the tumor suppressor gene. N Engl J Med 1993; 329:1318-1327.